Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of Daxdilimab in Moderate-to-Severe Primary Discoid Lupus Erythematosus
2022-000831-21Phase 2Active
- Sponsor
- Horizon Therapeutics
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in discoid lupus erythematosus (DLE) comparing Daxdilimab with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Dec 2022; status: active.
02
Drugs
daxdilimab
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on 2022-000831-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000831-21.